Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Shara is active.

Publication


Featured researches published by Michael Shara.


Molecular and Cellular Biochemistry | 2004

Physico-chemical properties of a novel (-)-hydroxycitric acid extract and its effect on body weight, selected organ weights, hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological changes over a period of 90 days

Michael Shara; Sunny E. Ohia; Robert E. Schmidt; Taharat Yasmin; Andrea Zardetto-Smith; Manashi Bagchi; Archana Chatterjee; Debasis Bagchi; Sidney J. Stohs

Garcinia cambogia-derived (—)-hydroxycitric acid (HCA) is a popular and natural supplement for weight management. HCA is a competitive inhibitor of the enzyme ATP citrate lyase, which catalyzes the conversion of citrate and coenzyme A to oxaloacetate and acetyl coenzyme A (acetyl CoA) in the cytosol. Acetyl CoA is used in the synthesis of fatty acids, cholesterol and triglycerides, and in the synthesis of acetylcholine in the central nervous system. Studies have demonstrated the efficacy of a novel 60% calcium-potassium salt of HCA derived from Garcinia cambogia(HCA-SX, Super CitriMax) in weight management. Results have shown that HCA-SX promotes fat oxidation, enhances serotonin release and availability in the brain cortex, normalizes lipid profiles, and lowers serum leptin levels in obese subjects. Acute oral, acute dermal, primary dermal irritation and primary eye irritation toxicity, as well as Ames bacterial reverse mutation studies and mouse lymphoma tests have demonstrated the safety of HCA-SX. However, no detailed long-term safety of HCA-SX or any other HCA extract has been previously assessed. We evaluated the dose- and time-dependent effects of HCA-SX in Sprague-Dawley rats on body weight, selected organ weights, hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry over a period of 90 days. Furthermore, a 90-day histopathological evaluation was conducted. The animals were treated with 0, 0.2, 2.0 and 5.0% HCA-SX of feed intake and were sacrificed on 30, 60 or 90 days of treatment. The body weight and selected organ weights were assessed and correlated as a % of body weight and brain weight at 90 days of treatment. A significant reduction in body weight was observed in treated rats as compared to control animals. An advancing age-induced marginal increase in hepatic lipid peroxidation was observed in both male and female rats, while no such difference in hepatic DNA fragmentation was observed as compared to the control animals. Furthermore, selected organ weights individually and as a % of body weight and brain weight at 90 days of treatment exhibited no significant difference between the groups. No difference was observed in hematology and clinical chemistry or the histopathological evaluation. Taken together, these results show that 90 day treatment of HCA-SX results in a reduction in body weight, and does not cause any changes in major organs or in hematology, clinical chemistry, and histopathology.


Molecular and Cellular Biochemistry | 2003

Dose- and time-dependent effects of a novel (-)-hydroxycitric acid extract on body weight, hepatic and testicular lipid peroxidation, DNA fragmentation and histopathological data over a period of 90 days

Michael Shara; Sunney E. Ohia; Taharat Yasmin; Andrea Zardetto-Smith; Manashi Bagchi; Archana Chatterjee; Debasis Bagchi; Sidney J. Stohs

Abstract(−)-Hydroxycitric acid (HCA), a natural extract from the dried fruit rind of Garcinia cambogia (family Guttiferae), is a popular supplement for weight management. The dried fruit rind has been used for centuries as a condiment in Southeastern Asia to make food more filling and satisfying. A significant number of studies highlight the efficacy of Super CitriMax (HCA-SX, a novel 60% calcium-potassium salt of HCA derived from Garcinia cambogia) in weight management. These studies also demonstrate that HCA-SX promotes fat oxidation, inhibits ATP-citrate lyase (a building block for fat synthesis), and lowers the level of leptin in obese subjects. Acute oral, acute dermal, primary dermal irritation and primary eye irritation toxicity studies have demonstrated the safety of HCA-SX. However, no long-term safety of HCA-SX or any other (−)-hydroxycitric acid extract has been previously assessed. In this study, we have evaluated the dose- and time-dependent effects of HCA-SX in Sprague-Dawley rats on body weight, hepatic and testicular lipid peroxidation, DNA fragmentation, liver and testis weight, expressed as such and as a % of body weight and brain weight, and histopathological changes over a period of 90 days. The animals were treated with 0, 0.2, 2.0 and 5.0% HCA-SX as feed intake and the animals were sacrificed on 30, 60 or 90 days of treatment. The feed and water intake were assessed and correlated with the reduction in body weight. HCA-SX supplementation demonstrated a reduction in body weight in both male and female rats over a period of 90 days as compared to the corresponding control animals. An advancing age-induced marginal increase in hepatic lipid peroxidation was observed in both male and female rats as compared to the corresponding control animals. However, no such difference in hepatic DNA fragmentation and testicular lipid peroxidation and DNA fragmentation was observed. Furthermore, liver and testis weight, expressed as such and as a percentage of body weight and brain weight, at 30, 60 and 90 days of treatment, exhibited no significant difference between the four groups. Taken together, these results indicate that treatment of HCA-SX over a period of 90 days results in a reduction in body weight, but did not cause any changes in hepatic and testicular lipid peroxidation, DNA fragmentation, or histopathological changes.


Molecular and Cellular Biochemistry | 2007

Cytokine expression due to Helicobacter pylori in a tissue culture model

Kristin Berg; Archana Chatterjee; Taharat Yasmin; Michael Shara; Debasis Bagchi

Helicobacter pylori, in recent years, has been recognized as the major causative agent in chronic gastritis and peptic ulcer disease in humans. H. pylori is a ubiquitous organism, with at least half of the world’s population infected. Of those individuals with peptic ulcer disease, it is estimated that 90% of cases are caused by H. pylori. Currently, the efficacy of therapies is starting to decline due to increasing resistance rates, especially towards clarithromycin. Due to this, new therapies are needed to combat this bacterium. It is hypothesized that cytokine release (especially interleukin-1β, -6, -8, and TNF-α) due to H. pylori infection and the subsequent influx of inflammatory cells causes a massive release of reactive oxygen species (ROS) during the inflammatory reaction. The ROS then cause the pathologic changes seen in the infected tissues. In this study, human gastric adenocarcinoma cell line ATCC 1739 (a cell line not previously evaluated) was examined for its production of interleukin-1β, -6, -8, and TNF-α when cocultured in a ratio of 10:1 H. pylori to adenocarcinoma cells, to determine its value as a model to demonstrate the inflammatory response. Results from this study indicated that ATCC 1739 cells only reliably produced IL-8 when cocultured with H. pylori and stimulated with TNF-α. The production of IL-1β, IL-6, and TNF-α by the ATCC 1739 cells was no different in H. pylori-exposed cells than non-exposed cells. It was concluded that the ATCC 1739 cell line is not suitable to study the effects of coculture with H. pylori on cytokine production.


Toxicology Mechanisms and Methods | 2006

Safety Assessment of a Novel Niacin-Bound Chromium-Based Energy Formulation

Michael Shara; Taharat Yasmin; Archana Chatterjee; Manashi Bagchi; Nilanjana Maulik; Debasis Bagchi

Over 35 million adults suffer from fatigue or lack of energy. In this study, we assessed the safety of a novel niacin-bound chromium-based Energy Formulation, which also contained caffeine, D-ribose, Withania somnifera extract, and selected amino acids. Niacin-bound chromium is a novel source of bioavailable chromium (III), and known to promote healthy lipid profile. Male and female Sprague-Dawley rats were fed 125 ppm Energy Formulation for 90 consecutive days. Body weight, feed, and water intake were monitored over the period of 90 days. No significant changes were observed between the control and treatment groups following subchronic supplementation with this Energy Formulation. Furthermore, no significant changes were observed in selected organ weights individually and as percentages of body and brain weights. The Energy Formulation supplementation did not cause changes in hepatic lipid peroxidation or DNA fragmentation after 30, 60, or 90 days of treatment. Hematology, clinical chemistry, and histopathological evaluations revealed no adverse effects in the treatment group. These findings demonstrate the safety of this Energy Formulation.


Journal of Inorganic Biochemistry | 2005

Safety and toxicological evaluation of a novel niacin-bound chromium(III) complex

Michael Shara; Taharat Yasmin; Aimee L. Limpach; Jason C. Bartz; Karrie A. Brenneman; Archana Chatterjee; Manashi Bagchi; Sidney J. Stohs; Debasis Bagchi


Mutation Research | 2005

Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid

Bernard W. Downs; Manashi Bagchi; Gottumukkala V. Subbaraju; Michael Shara; Harry G. Preuss; Debasis Bagchi


Journal of Inorganic Biochemistry | 2007

Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex

Michael Shara; Aimee L. Limpach; Robert Sandstrom; Laura Barrett; Neil S Norton; James D. Bramble; Taharat Yasmin; Janet Tran; Archana Chatterjee; Manashi Bagchi; Debasis Bagchi


Archive | 2007

A Review of the Safety and Efficacy of Citrus aurantium in Weight Management

Sidney J. Stohs; Michael Shara


Biofactors | 2006

Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement.

Mahesh Thirunavukkarasu; SureshVarma Penumathsa; Bela Juhasz; Lijun Zhan; Manashi Bagchi; Taharat Yasmin; Michael Shara; Hemant S. Thatte; Debasis Bagchi; Nilanjana Maulik


Mutation Research | 2005

Bioefficacy of a novel calciumpotassium salt of (-)-hydroxycitric acid

Bernard W. Downs; Manashi Bagchi; Gottumukkala V. Subbaraju; Michael Shara; Harry G. Preuss; Debasis Bagchi

Collaboration


Dive into the Michael Shara's collaboration.

Top Co-Authors

Avatar

Debasis Bagchi

Creighton University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Manashi Bagchi

Creighton University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Taharat Yasmin

Creighton University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Archana Chatterjee

Creighton University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Aimee L. Limpach

Creighton University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Andrea Zardetto-Smith

Creighton University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Harry G. Preuss

Georgetown University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge